If you understand one thing structurally about this market, make it this. Peptides reach people through three distinct channels, and those channels are not tiers of the same thing at different price points. They are separate systems with separate legal bases and radically different obligations.
The comparison
| 503A pharmacy | 503B outsourcing facility | Research-use-only | |
|---|---|---|---|
| What it is | Traditional compounding pharmacy | Registered outsourcing facility | Chemical supplier |
| Prescription | Patient-specific, required | Not required for each unit | None |
| Scale | Individual preparations | Batch production | Unrestricted |
| FDA registration | No; state-licensed | Yes | No |
| CGMP obligations | No | Yes | No |
| Routine FDA inspection | Not routinely | Yes | No |
| Governing bulks list | 503A Bulks List | Separate 503B list | None |
| Intended for humans | Yes | Yes | Explicitly not |
503A: traditional compounding
A state-licensed pharmacy preparing a medication for one identified patient against a valid prescription. This is the oldest form of pharmacy practice and the one most people picture.
The constraint that governs everything: a 503A pharmacy may use a bulk drug substance only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug product, or appears on the 503A Bulks List. Three doors, and a substance needs one of them.
This is the system the July 2026 vote was about. The committee was deciding whether six peptides should be added to that third door.
503B: outsourcing facilities
Created by the Drug Quality and Security Act of 2013 in the aftermath of a fungal meningitis outbreak traced to contaminated compounded injections. The category exists to cover a real gap: hospitals and clinics needing batch-produced sterile preparations without a prescription for each unit.
The trade-off is oversight. Outsourcing facilities register with the FDA, operate under current good manufacturing practice requirements, and are subject to routine FDA inspection. They also work from a separate bulks list with its own criteria.
The July meeting did not address 503B
This is frequently missed. The proceeding concerned the 503A bulks list only. Even a completed 503A rule would not authorize outsourcing facilities to batch-produce these peptides. Future advisory meetings may take up 503B authorities, but that has not happened.
Research-use-only
The third channel is not a pharmacy channel at all. Research-use-only suppliers sell chemical material labeled explicitly not for human consumption, and that labeling is the legal basis for selling it without a prescription or drug approval.
What the label carries with it is the absence of the obligations attached to the other two columns. No requirement that the active ingredient come from an FDA-registered supplier. No pharmacist verification. No patient-specific prescription. No CGMP. No routine inspection. No adverse-event reporting duty.
Reputable suppliers in this channel publish third-party analytical documentation voluntarily, and that voluntary practice is the main quality signal available. It is a meaningful signal. It is not the same as a regulatory requirement, because nothing obliges a supplier to publish an unfavorable result.
Why the distinction is load-bearing
Across the entire July review, the recurring objection from FDA scientists was characterization — whether a substance can be reliably identified and quantified. Reviewers applied a four-factor framework covering physical and chemical characterization, historical use in compounding, evidence of effectiveness, and safety, and concluded none of the seven satisfied the criteria.
That objection was aimed at the regulated channel, where sourcing standards would apply. It applies with considerably more force where no standards apply at all.
What a legalized 503A pathway would and wouldn't change
- Would: create a lawful route via prescription, with API from FDA-registered suppliers and pharmacist oversight.
- Wouldn't: change research-use-only material, which sits outside the pharmacy system entirely.
- Wouldn't: authorize 503B batch production, which is governed by a separate list.
- Wouldn't: override stricter state pharmacy board standards.
The state layer
State boards of pharmacy regulate compounding independently and can be more restrictive than federal baseline. Ohio's board has issued explicit guidance that Category 2 and Category 3 peptides cannot be compounded, and has taken enforcement action — including summary suspension in some cases — against pharmacies working with restricted peptides including BPC-157 and CJC-1295/ipamorelin.
A federal rule would not automatically displace a stricter state standard. Anyone tracking this needs to watch both levels.
Common questions
503A is a pharmacy preparing a medication for one identified patient against a prescription. 503B is a registered outsourcing facility batch-producing preparations under CGMP requirements and routine FDA inspection, without needing a prescription for each unit. They operate from separate bulks lists.
No. It concerned the 503A bulks list only. Even a completed 503A rule would not authorize outsourcing facilities to batch-produce these peptides.
Not necessarily lower, but unverified by any external requirement. Reputable suppliers publish third-party analytical documentation voluntarily, which is a real signal — though nothing compels a supplier to publish an unfavorable result.
It was created by the Drug Quality and Security Act of 2013 after a fungal meningitis outbreak traced to contaminated compounded injections, to cover facilities producing batch sterile preparations for hospitals and clinics.
Yes. State boards of pharmacy set their own standards, and several already prohibit compounding of restricted peptides. A federal rule would not automatically override a stricter state position.
Sources
- US Food and Drug Administration. PCAC meeting, July 23–24, 2026. Meeting docket FDA-2026-N-2979; bulk substances docket FDA-2025-N-6895. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” July 27, 2026.
- Orrick. “FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting.” July 2026.
- Sheppard Mullin. “Compounded Peptides on the Loose: What the Recent PCAC Meeting Means for Industry.” August 2026.